Show simple item record

dc.creatorGutiérrez, José María
dc.creatorSolano Trejos, María Gabriela
dc.creatorPla Ferrer, Davinia
dc.creatorHerrera Vega, María
dc.creatorSegura Ruiz, Álvaro
dc.creatorVillalta Arrieta, Mauren
dc.creatorVargas Arroyo, Mariángela
dc.creatorSanz, Libia
dc.creatorLomonte, Bruno
dc.creatorCalvete Chornet, Juan José
dc.creatorLeón Montero, Guillermo
dc.date.accessioned2017-06-09T20:16:58Z
dc.date.available2017-06-09T20:16:58Z
dc.date.issued2013-07
dc.identifier.citationhttp://www.sciencedirect.com/science/article/pii/S0041010112008112es_ES
dc.identifier.issn0041-0101
dc.identifier.urihttp://hdl.handle.net/10669/30085
dc.description.abstractThe assessment of the capacity of antivenoms to neutralize the lethal activity of snake venoms is the gold standard in the preclinical analysis of antivenom efficacy, and is routinely performed by manufacturers and quality control laboratories. However, the complexity of snake venom composition and toxicological profile demands that, for many venoms, such as those of viperid snakes and some elapids, the neutralization of lethality be complemented with the analysis of the neutralization of other relevant toxic activities, such as hemorrhagic, myotoxic, necrotizing, procoagulant and defibrinogenating effects. This expanded protocol for preclinical testing of antivenoms should be used when a new antivenom is developed or when an existing antivenom is introduced in a new geographical setting for the neutralization of either homologous or heterologous venoms. In recent years, the assessment of the immunological reactivity of antivenoms has been enriched by the use of proteomic tools, with a methodology named ‘antivenomics’. This allows the identification of venom components to which antivenoms have, or lack, antibodies, and thus complements the data gathered in neutralization tests, paving the way for a knowledge-based improvement of antivenom design and efficacy. International projects involving participants of manufacturing, quality control and academic research groups should be promoted in order to gain a deeper understanding on the preclinical neutralizing spectrum of antivenoms.es_ES
dc.description.sponsorshipUniversidad de Costa Rica//UCR/Costa Ricaes_ES
dc.description.sponsorship//CRUSA-CSIC/Españaes_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad/[BFU2010-17373]//Españaes_ES
dc.description.sponsorshipGeneralitat Valenciana/[PROMETEO/2010/005]//Españaes_ES
dc.language.isoen_USes_ES
dc.sourceToxicon Volumen 69. 2013es_ES
dc.subjectAntivenomses_ES
dc.subjectNeutralizationes_ES
dc.subjectPotency testes_ES
dc.subjectAntivenomicses_ES
dc.subjectSnake venomes_ES
dc.titleAssessing the preclinical efficacy of antivenoms: From the lethality neutralization assay to antivenomicses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.1016/j.toxicon.2012.11.016
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.identifier.pmid23201503


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record